Clinical trial
A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Sertraline 100 mg Tablets Under Fasting Conditions
NCT00864344 is registered in ClinicalTrials.gov with Actavis Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Sertraline 100 mg Tablets Under Fasting Conditions
- Lead sponsor
- Actavis Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2004
- Completion date
- August 31, 2004
- Enrollment
- 30 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy